Pulmatirx (Lexington, MA) a clinical-stage biotech company focused on COPD and astham, closed a $14M Series B financing. Participants include Polaris Venture Partners, 5AM Ventures, Arch Venture Partners and Novartis Venture Fund.
Thanx for your patience as we catch-up.

Ceptaris Therapeutics (Malvern, PA) a clinical-stage specialty pharmaceutical company focused on the treatment of mycosis fungoides, a type of cutaneous t-cell lymphoma, closed a $14.4M Series D financing. Participants include Vivo Ventures, Palo Alto Investors, Burrill & Co. and Aperture Venture Partners.
Thanx for your patience as we catch-up.

ZocDoc (New York, NY) a commercial-stage web-based healthcare provider network and appointment service, closed a $25M Series C, bringing the total financing to $75M. Participants inculde Goldman Sachs and DST Global.

Allegro Diagnostics (Maynard, MA) a development-stage molecular diagnostics company focused on genomic tests for the diagnosis of lung cancer, closed a $5.4M Series A financing. Participants include Kodiak Venture Partners and Catalyst Health Ventures.

Tensha Therapeutics (Cambridge, MA) a preclinical-stage pharmaceutical company focused on midline carcinoma, acute myeloid leukemias and multiple myeloma, closed a $15M Series A financing. Participants include HealthCare Ventures.

Tokai Pharmaceuticals (Cambridge, MA) a clinical-stage pharmaceutical company focused on prostate cancer, closed a $23M Series D financing. Participants include Novartis Venture Fund and Apple Tree Partners.

Valeritas (Bridgewater, NJ) a commercial-stage developer of a disposable insulin delivery device, closed a $150M Series C financing. Participants include Welsh, Carson, Anderson & Stowe, MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, Onset Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures.

Putney (Portland, ME) a commercial-stage pharmaceutical company focused on bioequivalents and specialty drugs for the veterinary market, closed a $21M Series C financing. Participants include NewSpring Health Capital and Safeguard Scientifics.

RF Biocidics (Boston, MA) a development-stage device company focused on the elimination of food related pathogens and fungi, closed a $10M Series B financing. Participants include Allied Minds and Invesco Asset Management.

ProtonMedia (Landsdale, PA) a commercial-stage cloud-based life science product lifecycle project management platform, closed a $4.5M Series B financing. Participants include Kaplan Ventures.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach >45,000 high-value targeted life science professionals on-line and in-print. Contact arubenstein@rnaventures.com for details.

Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on small molecule therapeutics against chromatin-based targets to treat cancer and inflammatory disorders, closed a $15M Series B financing bringing the total round to $37M. Participants include S.R. One, Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.
The 2Q11 OnBioVC Trend Analysis will be [...]

Novophage (Boston, MA) a development-stage synthetic biology company focused on antimicrobial biofilms, closed a $5.7M Series A financing. Participants include Flybridge Capital Partners, Chevron Technology Ventures, Founder Collective and The Kraft Group.

Lotus Tissue Repair (Cambridge, MA) a development-stage biopharmaceutical company focused on dystrophic epidermolysis bullosa and other dermatologic conditions, closed a $26M Series A financing. Participants include Third Rock Ventures.